StreetAlpha.app
Home › Stocks › SCYX

Scynexis Inc (SCYX)

$2.38
▼ −8.64%
LAST CLOSE · NOV 20

SCYNEXIS develops antifungal drugs for hard to treat fungal infections, aimed at hospital patients and the physicians who treat them. It last closed at $2.38 on Nov 20, down 8.64% on the day. For the quarter ended Sep 2026, SCYX reported EPS of -$0.71 on revenue of $0, with revenue down 100.0% from a year ago. Over its last 6 reports the stock moved an average of 8.0% the session after earnings.

AI Auto Pilots
Is SCYX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold SCYX.

Key Stats

Last 12 months
Results
Revenue
$18.9M
+544.0% vs a year ago
Net income
−$10.1M
−53.5% margin
Operating margin
−126.9%
−$24.0M operating income
Valuation
Market cap
$23.7M
10.0M shares
P/E
–
Price to sales
1.3
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$8.2M
At Sep 30
Shareholder equity
$59.0M
Shares outstanding
10.0M
At Nov 1
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $13.2M$13.2MFY2021FY2022: $5.1M$5.1MFY2022FY2023: $140.1M$140.1MFY2023FY2024: $3.7M$3.7MFY2024FY2025: $20.6M$20.6MFY2025

From SCYX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Last report
Mar 28
2024 · next date not set yet
Reported EPS
-$0.71
Quarter ended Sep 2026
Year ago EPS
-$1.38
Same quarter last year
Revenue
$0
−100.0% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.09Dec '24Mar 2025: -$0.11Mar '25Jun 2025: -$1.11Jun '25Sep 2025: -$1.38Sep '25Dec 2025: $3.19Dec '25Mar 2026: -$0.42Mar '26Jun 2026: $0.63Jun '26Sep 2026: -$0.71Sep '26Latest -$0.71
Revenue by quarter
Dec 2024: $977,000Dec '24Mar 2025: $257,000Mar '25Jun 2025: $1.4MJun '25Sep 2025: $334,000Sep '25Dec 2025: $18.6MDec '25Mar 2026: $0Mar '26Jun 2026: $235,000Jun '26Sep 2026: $0Sep '26Latest $0
How SCYX moved after its last 6 reports
Average move the session after a report ±8.0%
Mar 28, 2024After the close+1.4%
Nov 9, 2022Time not announced−19.6%
Aug 15, 2022Time not announced+2.1%
May 12, 2022After the close+10.7%
Mar 29, 2022Time not announced−13.0%
Nov 10, 2021Time not announced+1.3%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on SCYXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on SCYX
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on SCYX

Technical Analysis

SCYX · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 43% below its 20 day and 67% below its 50 day average. It is 125% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 19), oversold. The nearest support is the 52 week low at $2.30, and the nearest resistance the Pivot at $2.47.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 12.1%/day
Key levels
$9.1252 week high+283.2%
$5.35200 day average+124.8%
$4.38100 day average+84.0%
$3.9850 day average+67.2%
$3.98Swing high (Oct 21)+67.2%
$3.4120 day average+43.3%
$2.64Pivot R1+10.9%
$2.47Pivot+3.8%
$2.38Last close
$2.3052 week low−3.4%
$2.21Pivot S1−7.1%
Indicators
RSI (14)19.40Oversold below 30Oversold
MACD-0.39Below its signal lineBearish
Stochastic6.8Near the bottom of its rangeOversold
ADX (14)34.8Trending down
Williams %R-95.3Oversold below −80, overbought above −20Oversold
CCI (20)-176.7Oversold below −100, overbought above 100Oversold
Rate of change−32.0%Change over 10 sessionsBearish
ATR (14)$0.29Typical daily range, 12.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for SCYX

What happened before

See how SCYX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow SCYX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How SCYX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for SCYXHow many large options trades hit SCYX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

SCYX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●15 buying vs 17 selling
  • ▼Held by funds -4.9 pts
  • ▲Funds holding +2
  • ▼Superinvestors: 0 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding4240+5.0%
In funds' top 1000–
Held by funds46.8%51.7%−4.9 pts
New / increased7 / 840 / 0−62.5%
Reduced / sold out12 / 50 / 44−61.4%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See SCYX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SCYX is in one of them and how their past SCYX trades turned out.

SCYX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered SCYX in an article yet. Here's the latest on the wider market.

About Scynexis

SCYNEXIS is a pharmaceutical company based in Jersey City, New Jersey, that develops antifungal medicines. Its approved product, BREXAFEMME, treats vaginal yeast infections, and it has been licensed to GSK. Its main development candidate, SCY-247, is an oral and intravenous antifungal being studied for serious fungal infections, mainly in hospital patients with weakened immune systems and in other patients at high risk. The company's customers are mainly physicians at major medical centers who treat these patients.

Headquarters
Jersey City, NJ